Table: Santen Pharm -Q1 group results (IFRS)
03/08/2023 07:00
Aug 3 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2023 Jun 30, 2022 Mar 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 72.39 65.53 273.00
(+10.5 pct) (+0.8 pct) (-2.2 pct)
Operating 12.75 8.33 32.00
(+53.0 pct) (-9.0 pct)
Pretax 12.87 9.07 29.80
(+41.8 pct) (-1.1 pct)
Net 10.41 6.66
(+56.3 pct) (-9.2 pct)
EPS Basic 27.93 yen 16.79 yen 61.24 yen
EPS Diluted 27.85 yen 16.77 yen
Ann Div 32.00 yen 32.00 yen
-Q2 Div 16.00 yen 16.00 yen
-Q4 Div 16.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T